Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease

Journal of Neuroscience

Volumn 37, Issue 3, 2017, Pages 637-647

  Jay, Taylor R ^a,b   Hirsch, Anna M ^a   Broihier, Margaret L ^a   Miller, Crystal M ^b   Neilson, Lee E ^a   Ransohoff, Richard M ^c   Lamb, Bruce T ^a,d   Landreth, Gary E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BIOGEN   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AD; Genetic risk factor; Inflammation; Microglia; Myeloid cell; Neuroinflammation

Indexed keywords

TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AMYLOID PLAQUE; ANIMAL CELL; BONE MARROW CELL; CONTROLLED STUDY; DISEASE EXACERBATION; GENE FUNCTION; GENETIC DAMAGE; GENETIC RISK; HUMAN; INTERNALIZATION (CELL); MICROGLIA; MOLECULAR PATHOLOGY; RISK FACTOR; TREM2 GENE; ANIMAL; BRAIN; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC;

EID: 85010369316     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2110-16.2016     Document Type: Article

References (38)

1. Benitez BA et al. (2014) Missense variant in TREML2 protects against Alzheimer’s disease. Neurobiol Aging 35:1510 e19-26.
2. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, Weissman IL, Chang EF, Li G, Grant GA, Hayden Gephart MG, Barres BA (2016) New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113:E1738-E1746.
3. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014) Identification of a unique TGF- dependent molecular and functional signature in microglia. Nat Neurosci 17:131-143.
4. Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L (2015) TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol 129:429-447.
5. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85: 519-533.
6. Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3:445-453.
7. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432-438.
8. Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56:1438-1447.
9. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T (2010) Macrophages in Alzheimer’s disease: the blood-borne identity. J Neural Transm 117:961-970.
10. Guerreiro R et al. (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117-127.
11. Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K, Town T (2015) Deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85:534-548.
12. Heneka MT et al. (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388-405.
13. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) Arole forTREM2ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109:1144-1156.
14. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24:173-182.
15. Jay TR et al. (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med 212:287-295.
16. Jiang T, Wan Y, Zhang YD, Zhou JS, Gao Q, Zhu XC, Shi JQ, Lu H, Tan L, Yu JT (2016) TREM2 overexpression has no improvement on neuropathology and cognitive impairment in aging APPswe/PS1dE9 mice. Mol Neurobiol. In press.
17. Jonsson T et al. (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107-116.
18. Kang W, Balordi F, Su N, Chen L, Fishell G, Hébert JM (2014) Astrocyte activation is suppressed in both normal and injured brain by FGF signaling. Proc Natl Acad Sci U S A 111:E2987-E2995.
19. Karch CM, Goate AM (2015) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77:43-51.
20. Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Nakamura MC, Yenari MA (2015) Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke. J Neurosci 35:3384-3396.
21. Kleinberger G et al. (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6:243 ra286.
22. Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Li S, Ljubimov V, Moyseyev M, Daley D, Fuchs DT, Pham M, Black KL, Rentsendorj A, Koronyo-Hamaoui M (2015) Therapeutic effects of glatiramer acetate and grafted CD115(+) monocytes in a mouse model of Alzheimer’s disease. Brain 138:2399-2422.
23. Lill CM et al. (2015) The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimers Dement 11:1407-1416.
24. McGeer PL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79:195-200.
25. Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, Stalder AK, Staufenbiel M, Neumann H, Carson MJ (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic ice: implications for vaccine-based therapies for Alzheimer’s disease. ASN Neuro 2:e00037.
26. Montalvo V, Quigley L, Vistica BP, Boelte KC, Nugent LF, Takai T, McVicar DW, Gery I (2013) Environmental factors determine DAP12 deficiency to either enhance or suppress immunopathogenic processes. Immunology 140:475-482.
27. Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, Colonna M (2012) TREM2 and betacatenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 188:2612-2621.
28. Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M (2015) TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125:2161-2170.
29. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jäggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Hölscher C, Mathews PM, Jucker M (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7:940-946.
30. Replogle RA, Chan G, White CC, Raj T, Winn PA, Evans DA, Sperling RA, Chibnik LB, Bradshaw EM, Schneider JA, Bennett DA, De Jager PL (2015) A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann Neurol 77:469-477.
31. Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ (2002) Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem 83:1309-1320.
32. Scott E, Simon MC, Anastasi J, Singh H (1994) Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265:1573-1577.
33. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201:647-657.
34. Tanzi RE (2015) TREM2 and Risk of Alzheimer’s Disease— Friend or Foe? N Engl J Med 372:2564-2565.
35. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM (2014) Altered microglial response to A_ plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9:20-20.
36. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160:1061-1071.
37. Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M (2016) TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213:667-675.
38. Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J (2016) TREM2haploinsufficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90:724-739.